Finance in biotech and medtech
biotech/medtech finance: burn rate and runway, milestone-based funding and partnerships, valuing pre-revenue pipelines, and reimbursement as the real gate.
Finance in Biotech and MedTech operates under conditions few other sectors face: long pre-revenue horizons, binary clinical outcomes, patent cliffs, and reimbursement uncertainty. This block builds sector-specific financial fluency for professionals who must value assets before they generate cash, model milestone-driven cash flows, and read the burn rate of a company years from market. You will apply core finance concepts to risk-adjusted NPV of drug and device pipelines, learn the metrics and benchmarks investors and analysts actually use across US and European markets, and master the financial regulation, risks, and due-diligence checks that distinguish credible programs from value traps. The emphasis throughout is practical, quantitative, and grounded in how capital really flows through this sector.
Ce que vous allez maîtriser
- Build a risk-adjusted NPV model for a drug or device pipeline incorporating phase-transition probabilities and milestone payments
- Calculate and interpret sector-specific metrics such as cash runway, burn rate, and R&D capitalization against US and European benchmarks
- Assess a company's financing structure and dilution risk across funding rounds, grants, and non-dilutive capital
- Perform financial due diligence on a biotech or medtech target, identifying reimbursement, regulatory, and IP-linked financial risks